Abstract
Oridonin is one of the major components isolated from Isodon rubescens, a traditional Chinese medicine, and it has been confirmed to exhibit many kinds of biological activities including anticancer, anti-inflammation, antibacterial and so on. However, the poor pharmaceutical property limits the clinical applications of oridonin. So many strategies have been explored in the purpose of improving the potencies of oridonin, and structure modification is one thus way. This review outlines the landscape of the recent development of oridonin derivatives with diverse pharmacological activities, mainly focusing on the biological properties, structure-activity relationships, and mechanism of actions.
Keywords: Derivative, mechanism of action, oridonin, pharmaceutical activity, structure modification, structure-activity relationship.
Graphical Abstract
[1]
Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod., 2016, 79(3), 629-661.
[2]
Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod., 2012, 75(3), 311-335.
[3]
Patridge, E.; Gareiss, P.; Kinch, M.S.; Hoyer, D. An analysis of FDA-approved drugs: Natural products and their derivatives. Drug Discov. Today, 2016, 21(2), 204-207.
[4]
Mishra, B.B.; Tiwari, V.K. Natural products: An evolving role in future drug discovery. Eur. J. Med. Chem., 2011, 46(10), 4769-4807.
[5]
Harvey, A.L.; Edrada-Ebel, R.; Quinn, R.J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov., 2015, 14(2), 111-129.
[6]
Katz, L.; Baltz, R.H. Natural product discovery: Past, present, and future. J. Ind. Microbiol. Biot., 2016, 43(2-3), 155-176.
[7]
Weng, Z.Y.; Huang, S.X.; Li, M.L.; Zeng, Y.Q.; Han, Q.B.; Rios, J.L.; Sun, H.D. Isolation of two bioactive ent-Kauranoids from the leaves of Isodon xerophilus. J. Agr. Food Chem., 2007, 55(15), 6039-6043.
[8]
Li, X.; Pu, J.; Jiang, S.; Su, J.; Kong, L.; Mao, B.; Sun, H.; Li, Y. Henryin, an ent-kaurane diterpenoid, inhibits Wnt signaling through interference with β-catenin/TCF4 interaction in colorectal cancer cells. PLoS One, 2013, 8(7), e68525.
[9]
Ma, Y.C.; Su, N.; Shi, X.J.; Zhao, W.; Ke, Y.; Zi, X.; Zhao, N.M.; Qin, Y.H.; Zhao, H.W.; Liu, H.M. Jaridonin-induced G2/M phase arrest in human esophageal cancer cells is caused by reactive oxygen species-dependent Cdc2-tyr15 phosphorylation via ATM-Chk1/2-Cdc25C pathway. Toxicol. Appl. Pharm., 2015, 282(2), 227-236.
[10]
Xu, Y.; Liu, J.; Wu, Y.; Guo, Q.; Sun, H.; Chen, G. Natural products against hematological malignancies and identification of their targets. Sci. China Life Sci., 2015, 58(12), 1191-1201.
[11]
Zhao, Z.; Chen, Y. Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies. Curr. Pharm. Biotech., 2014, 15(11), 1083-1092.
[12]
Hsieh, T.C.; Wijeratne, E.K.; Liang, J.Y.; Gunatilaka, A.L.; Wu, J.M. Differential control of growth, cell cycle progression, and expression of NF-kappa B in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem. Bioph. Res. Commun., 2005, 337(1), 224-231.
[13]
Ma, Y.C.; Ke, Y.; Zi, X.; Zhao, W.; Shi, X.J.; Liu, H.M. Jaridonin, a novel ent-kaurene diterpenoid from isodon rubescens, inducing apoptosis via production of reactive oxygen species in esophageal cancer cells. Curr. Cancer Drug Tar., 2013, 13(6), 611-624.
[14]
Liu, X.; Yang, J.; Wang, W.G.; Li, Y.; Wu, J.Z.; Pu, J.X.; Sun, H.D. Diterpene alkaloids with an aza-ent-kaurane skeleton from isodon rubescens. J. Nat. Prod., 2015, 78(2), 196-201.
[15]
Kang, N.; Cao, S.J.; Zhou, Y.; He, H.; Tashiro, S.I.; Onodera, S.; Qiu, F.; Ikejima, T. Inhibition of caspase-9 by oridonin, a diterpenoid isolated from Rabdosia rubescens, augments apoptosis in human laryngeal cancer cells. Int. J. Oncol., 2015, 47(6), 2045-2056.
[16]
Ma, S.; Tan, W.; Du, B.; Liu, W.; Li, W.; Che, D.; Zhang, G. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression. Mol. Med. Rep., 2016, 13(4), 3342-3348.
[17]
Ren, C.M.; Li, Y.; Chen, Q.Z.; Zeng, Y.H.; Shao, Y.; Wu, Q.X.; Yuan, S.X.; Yang, J.Q.; Yu, Y.; Wu, K.; He, B.C.; Sun, W.J. Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK. Oncol. Rep., 2016, 35(5), 2691-2698.
[18]
Ikezoe, T.; Chen, S.S.; Tong, X.J.; Heber, D.; Taguchi, H.; Koeffler, H.P. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int. J. Oncol., 2003, 23(4), 1187-1193.
[19]
Huang, S.X.; Zhao, Q.S.; Xu, G.; Xiao, W.L.; Li, R.T.; Hou, A.J.; Peng, S.L.; Ding, L.S.; Sun, H.D. ent-kaurane diterpenoids from Isodon albopilosus. J. Nat. Prod., 2005, 68(12), 1758-1762.
[20]
Wang, L.; Wang, S.; Chen, R.; Wang, Y.; Li, H.; Wang, Y.; Chen, M. Oridonin loaded solid lipid nanoparticles enhanced antitumor activity in MCF-7 Cells. J. Nanomater., 2014.
[http://dx.doi.org/10.1155/2014/903646]
[http://dx.doi.org/10.1155/2014/903646]
[21]
Xu, Z.Z.; Fu, W.B.; Jin, Z.; Guo, P.; Wang, W.F.; Li, J.M. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma. Leukemia . Lymphoma, 2016, 57(4), 888-898.
[22]
Xu, W.; Sun, J.; Zhang, T.T.; Ma, B.; Cui, S.M.; Chen, D.W.; He, Z.G. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol. Sin., 2006, 27(12), 1642-1646.
[23]
Wen, X.U.; Jin, S.U.N.; Tingting, Z.; Bo, M.A.; Dawei, C.; Zhonggui, H.E. Determination of equilibrium solubility of oridonin and its apparent oil/water partition coefficient by HPLC. J. Shenyang Pharm. Univ., 2007, 24(4), 220-222.
[24]
Zhang, X.; Zhang, T.; Lan, Y.; Wu, B.; Shi, Z. Nanosuspensions
containing Oridonin/HP-β-cyclodextrin inclusion complexes for
oral bioavailability enhancement via improved dissolution and
permeability. Aaps Pharmscitech, 2016, 17(2), 400-408.
[25]
Liu, Y.; Zhang, P.; Feng, N.; Zhang, X.; Wu, S.; Zhao, J. Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin. Int. J. Pharm., 2009, 365(1-2), 136-142.
[26]
Li, S.; Liu, Y.; Liu, T.; Zhao, L.; Zhao, J.; Feng, N. Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int. J. Pharm., 2011, 411(1-2), 172-177.
[27]
Gao, L.; Zhang, D.; Chen, M.; Zheng, T.; Wang, S. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev. Ind. Pharm., 2007, 33(12), 1332-1339.
[28]
Ding, Y.; Ding, C.; Ye, N.; Liu, Z.; Wold, E.A.; Chen, H.; Wild, C.; Shen, Q.; Zhou, J. Discovery and development of natural product oridonin-inspired anticancer agents. Eur. J. Med. Chem., 2016, 122, 102-117.
[29]
Chen, R.Y.; Xu, B.; Chen, S.F.; Chen, S.S.; Zhang, T.; Ren, J.; Xu, J. Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer (BxPC-3) cells. World J. Gastroenterol., 2014, 20(40), 14895-14903.
[30]
Xu, S.; Pei, L.; Li, D.; Yao, H.; Cai, H.; Yao, H.; Wu, X.; Xu, J. Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives. Fitoterapia, 2014, 99, 300-306.
[31]
Fujita, E.; Nagao, Y.; Node, M.; Kaneko, K.; Nakazawa, S.; Kuroda, H. Antitumor activity of the Isodon diterpenoids: Structural requirements for the activity. Experientia, 1976, 32(2), 203-206.
[32]
Wang, S.; Yu, L.; Yang, H.; Li, C.; Hui, Z.; Xu, Y.; Zhu, X. Oridonin
attenuates synaptic loss and cognitive deficits in an Aβ-1-42-
induced mouse model of alzheimer's disease. Plos One, 2016, 11(3), //doi.org/10.1371/journal.pone.0151397.
[33]
Zhang, Z.Y.; Daniels, R.; Schluesener, H.J. Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J. Cell. Mol. Med., 2013, 17(12), 1566-1576.
[34]
Hu, A.P.; Du, J.M.; Li, J.Y.; Liu, J.W. Oridonin promotes CD4+/CD25+Treg differentiation, modulates Th1/Th2 balance and induces HO-1 in rat splenic lymphocytes. Inflamm. Res., 2008, 57(4), 163-170.
[35]
Liu, J.W.; Yang, F.; Zhang, Y.; Li, J.Y. Studies on the cell-immunosuppressive mechanism of oridonin from Isodon serra. Int. Immunopharmacol., 2007, 7(7), 945-954.
[36]
Zhou, L.; Sun, L.J.; Wu, H.K.; Zhang, L.Z.; Chen, M.C.; Liu, J.W.; Zhong, R.Q. Oridonin ameliorates lupus-like symptoms of MRLlpr/lpr mice by inhibition of B-cell activating factor (BAFF). Eur. J. Pharmacol., 2013, 715(1-3), 230-237.
[37]
Lee, E.J.; Cha, H.J.; Ahn, K.J.; An, I.S.; An, S.; Bae, S. Oridonin exerts protective effects against hydrogen peroxide-induced damage by altering microRNA expression profiles in human dermal fibroblasts. Int. J. Mol. Med., 2013, 32(6), 1345-1354.
[38]
Liu, G.A.; Ding, L.; Yang, Y.; Yang, H.; Yang, Q.M.; Wang, H.Q. Anti-oxidative action of ent-kaurene diterpenoids. Res. Chem. Intermed., 2006, 32(8), 787-794.
[39]
Murayama, C.; Nagao, Y.; Sano, S.; Ochiai, M.; Fuji, K.; Fujita, E.; Mori, T. Effect of oridonin, a Rabdosia diterpenoid, on radiosensitization with misonidazole. Experientia, 1987, 43(11-12), 1221-1223.
[40]
Chen, Q.; Wu, Q. M.; Cheng, J.; Ma, S.L.; Long, H. Study on the
radiosensitization effect of oridonin on esophageal cancer stem
cell. China J. Mod. Med.,, 2012, 29, 014.
[41]
Bohanon, F.J.; Wang, X.F.; Ding, C.Y.; Ding, Y.; Radhakrishnan, G.L.; Rastellini, C.; Zhou, J.; Radhakrishnan, R.S. Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. J. Surg. Res., 2014, 190(1), 55-63.
[42]
Zang, K.H.; Shao, Y.Y.; Zuo, X.; Rao, Z.; Qin, H.Y. Oridonin alleviates visceral hyperalgesia in a rat model of postinflammatory irritable bowel syndrome: Role of colonic enterochromaffin cell and serotonin availability. J. Med. Food, 2016, 19(6), 586-592.
[43]
Wang, L.X.; Sun, Y.; Chen, C.; Huang, X.Y.; Lin, Q.; Qian, G.Q.; Dong, W.; Chen, Y.F. Effects and mechanism of oridonin on pulmonary hypertension induced by chronic hypoxia-hypercapnia in rats. Chinese . Med. J., 2009, 122(12), 1380-1387.
[44]
Zhen, T.; Wu, C.F.; Liu, P.; Wu, H.Y.; Zhou, G.B.; Lu, Y.; Liu, J.X.; Liang, Y.; Li, K.K.; Wang, Y.Y.; Xie, Y.Y.; He, M.M.; Cao, H.M.; Zhang, W.N.; Chen, L.M.; Petrie, K.; Chen, S.J.; Chen, Z. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci. Transl. Med., 2012, 4(127)
[45]
Guo, Y.; Shan, Q.; Gong, Y.; Lin, J.; Yang, X.; Zhou, R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effects in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol. Ther., 2012, 13(13), 1244-1254.
[46]
Ming, M.; Sun, F.Y.; Zhang, W.T.; Liu, J.K. Therapeutic effect of oridonin on mice with prostate cancer. Asian Pac. J. Trop. Med., 2016, 9(2), 182-185.
[47]
Ding, C.; Zhang, Y.; Chen, H.; Yang, Z.; Wild, C.; Ye, N.; Ester, C.D.; Xiong, A.; White, M.A.; Shen, Q.; Zhou, J. Oridonin ring A-based diverse constructions of enone functionality: Identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J. Med. Chem., 2013, 56(21), 8814-8825.
[48]
Ding, C.; Wang, L.; Chen, H.; Wild, C.; Ye, N.; Ding, Y.; Wang, T.; White, M.A.; Shen, Q.; Zhou, J. ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids. Org. Biomol. Chem., 2014, 12(42), 8442-8452.
[49]
Ding, C.; Zhang, Y.; Chen, H.; Yang, Z.; Wild, C.; Chu, L.; Liu, H.; Shen, Q.; Zhou, J. Novel nitrogen-enriched oridonin analogues with thiazole-fused a-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J. Med. Chem., 2013, 56(12), 5048-5058.
[50]
Ding, C.; Zhang, Y.; Chen, H.; Wild, C.; Wang, T.; White, M.A.; Shen, Q.; Zhou, J. Overcoming synthetic challenges of oridonin A-ring structural diversification: Regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position. Org. Lett., 2013, 15(14), 3718-3721.
[51]
Wang, L.; Li, D.; Xu, S.; Cai, H.; Yao, H.; Zhang, Y.; Jiang, J.; Xu, J. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents. Eur. J. Med. Chem., 2012, 52, 242-250.
[52]
Li, D.; Cai, H.; Jiang, B.; Liu, G.; Wang, Y.; Wang, L.; Yao, H.; Wu, X.; Sun, Y.; Xu, J. Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells. Eur. J. Med. Chem., 2013, 59, 322-328.
[53]
Li, D.; Xu, S.; Cai, H.; Pei, L.; Zhang, H.; Wang, L.; Yao, H.; Wu, X.; Jiang, J.; Sun, Y.; Xu, J. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation. Eur. J. Med. Chem., 2013, 64, 215-221.
[54]
Li, D.; Xu, S.; Cai, H.; Pei, L.; Wang, L.; Wu, X.; Yao, H.; Jiang, J.; Sun, Y.; Xu, J. Library construction and biological evaluation of enmein-type diterpenoid analogues as potential anticancer agents. ChemMedChem, 2013, 8(5), 812-818.
[55]
Xu, J.; Yang, J.; Ran, Q.; Wang, L.; Liu, J.; Wang, Z.; Wu, X.; Hua, W.; Yuan, S.; Zhang, L.; Shen, M.; Ding, Y. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg. Med. Chem. Lett., 2008, 18(16), 4741-4744.
[56]
Li, D.; Han, T.; Xu, S.; Zhou, T.; Tian, K.; Hu, X.; Cheng, K.; Li, Z.; Hua, H.; Xu, J. Antitumor and antibacterial derivatives of oridonin: A main composition of Dong-Ling-Cao. Molecules, 2016, 21(5), pii: E575.
[http://dx.doi.org/10.3390/molecules21050575]
[http://dx.doi.org/10.3390/molecules21050575]
[57]
Wang, L.; Ran, Q.; Li, D.H.; Yao, H.Q.; Zhang, Y.H.; Yuan, S.T.; Zhang, L.Y.; Shen, M.Q.; Xu, J.Y. Synthesis and anti-tumor activity of 14-O-derivatives of natural oridonin. Chin. J. Nat. Med., 2011, 9(3), 194-198.
[58]
Liu, J.; Gao, J. Antitumor activity of components from isondon rubescens (hemsley) H. Hara and their acetyl derivatives predicted by michael addition reaction. Chem. Ind. For. Prod., 2016, 36(1), 27-34.
[59]
Fujita, E.; Nagao, Y.; Kohno, T.; Matsuda, M.; Ozaki, M. Terpenoids.46. anti-tumor activity of acylated oridonin. Chem. Pharm. Bull., 1981, 29(11), 3208-3213.
[60]
Wang, L.; Li, D.; Wang, C.; Zhang, Y.; Xu, J. Recent progress in the development of natural ent-kaurane diterpenoids with anti-tumor activity. Mini Rev. Med. Chem., 2011, 11(10), 910-919.
[61]
Zhang, W.; Huang, Q.; Hua, Z.C. Oridonin: A promising anticancer drug from China. Front. Biol., 2010, 5(6), 540-545.
[62]
Wang, C.; Jiang, L.; Wang, S.; Shi, H.; Wang, J.; Wang, R.; Li, Y.; Dou, Y.; Liu, Y.; Hou, G.; Ke, Y.; Liu, H. The antitumor activity of the novel compound jesridonin on human esophageal carcinoma cells. PLoS One, 2015, 10(6), e0130284.
[63]
Li, D.H.; Wang, L.; Cai, H.; Jiang, B.W.; Zhang, Y.H.; Sun, Y.J.; Xu, J.Y. Synthesis of novel furozan-based nitric oxide-releasing derivatives of 1-oxo-oridonin with anti-proliferative activity. Chin. J. Nat. Med., 2012, 10(6), 471-476.
[64]
Li, D.; Wang, L.; Cai, H.; Zhang, Y.; Xu, J. Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents. Molecules, 2012, 17(6), 7556-7568.
[65]
Xu, S.; Wang, G.; Lin, Y.; Zhang, Y.; Pei, L.; Yao, H.; Hu, M.; Qiu, Y.; Huang, Z.; Zhang, Y.; Xu, J. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies. Bioorg. Med. Chem. Lett., 2016, 26(12), 2795-2800.
[66]
Xu, S.; Pei, L.; Wang, C.; Zhang, Y.K.; Li, D.; Yao, H.; Wu, X.; Chen, Z.S.; Sun, Y.; Xu, J. Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates. ACS Med. Chem. Lett., 2014, 5(7), 797-808.
[67]
Xu, S.; Li, D.; Pei, L.; Yao, H.; Wang, C.; Cai, H.; Yao, H.; Wu, X.; Xu, J. Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives. Bioorg. Med. Chem. Lett., 2014, 24(13), 2811-2814.
[68]
Bohanon, F.J.; Wang, X.; Graham, B.M.; Ding, C.; Ding, Y.; Radhakrishnan, G.L.; Rastellini, C.; Zhou, J.; Radhakrishnan, R.S. Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis. J. Surg. Res., 2015, 199(2), 441-449.
[69]
Bohanon, F.J.; Wang, X.; Graham, B.M.; Prasai, A.; Vasudevan, S.J.; Ding, C.; Ding, Y.; Radhakrishnan, G.L.; Rastellini, C.; Zhou, J.; Radhakrishnan, R.S. Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells. Mol. Cell. Biochem., 2015, 410(1-2), 293-300.
[70]
Qiu, Z.; Chen, Y.; Sun, P.; Wu, G. New L-alanine-(14-oridonin)
ester trifluoroacetate salt useful for treating e.g. oesophageal cancer,
gastric cancer, primary liver cancer, pancreatic cancer, colorectal
cancer, bladder cancer and acute myeloid leukemia.
CN104017000-A, 03 Sep 2014 C07D-493/08 201509.
Related Books
Science of Spices and Culinary Herbs - Latest Laboratory, Pre-clinical, and Clinical Studies
Frontiers in Natural Product Chemistry
Therapeutic Use of Plant Secondary Metabolites
Therapeutic Implications of Natural Bioactive Compounds
Frontiers in Bioactive Compounds
Frontiers in Natural Product Chemistry
Frontiers in Natural Product Chemistry
Science of Spices and Culinary Herbs - Latest Laboratory, Pre-clinical, and Clinical Studies
Frontiers in Natural Product Chemistry
Frontiers in Natural Product Chemistry
Article Metrics
84
11